MolMed

April 17, 2019

Kiadis moves to reduce reliance on its in-house lead

Perhaps sensing trouble ahead Kiadis diversifies beyond ATIR101 by buying Cytosen, but it is a scientific appointment that will cause real excitement.

January 31, 2018

Bellicum’s cells not so controllable after all

May 09, 2017

ELCC – Physicians look for progress in mesothelioma

December 07, 2016

Ash interview – Kiadis preps for EU approval and US pivotal trial

August 05, 2016

Quiet revolution gets under way in stem cell transplantation

August 02, 2016

Pfizer’s $150m gene therapy Bamboo shoot

March 17, 2016

Revisiting a predictor of failure in the post-Celator world

December 05, 2015

ASH – Glaxo scores with second rare disease gene therapy

November 27, 2015

Upcoming events – Translarna and tremelimumab target underserved diseases